Recent Company News

• 08:30 AM ET Sep 09, 2026
  

  Takeda Phase 3 data on Oveporexton published in NEJM showing improved Narcolepsy Type 1 Symptoms and quality of life (¥5615.0000, 0)

• 03:07 AM ET Sep 07, 2026
  

  Heidelberg Pharma to present new clinical data on Pamlectabart Tismanitin at IMS Annual Meeting (€2.53, 0.00)

• 09:12 AM ET Sep 04, 2026
  

  StreetAccount Sector Summary - China Healthcare August Recap

• 03:06 PM ET Aug 31, 2026
  

  Afternoon headlines:

• 01:32 PM ET Aug 31, 2026
  

  Bayer, Takeda, CSL, others expected to announce drug pricing agreements with White House - media reports

• 08:44 AM ET Aug 31, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:40 PM ET Aug 28, 2026
  

  Protagonist Therapeutics issues press release on FDA approval of MIMRYLO to treat erythrocytosis in adults with PV; call to be held 31-Aug at 08:30 ET ($144.33, 0.00)

• 07:39 PM ET Aug 28, 2026
  

  Takeda issues press release on FDA approval of MIMRYLO to treat erythrocytosis in adults with PV (¥5800.0000, 0)

• 05:32 PM ET Aug 28, 2026
  

  FDA approves Mimrylo (rusfertide) as treatment for adults with polycythemia vera (¥5800.0000, 0)

• 03:13 PM ET Aug 28, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 30-Aug